The University of Chicago Header Logo

Connection

Richard A. Larson to Leukemia, Myeloid

Back to Details
This is a "connection" page, showing publications Richard A. Larson has written about Leukemia, Myeloid.
Richard A. Larson
Connection Strength
5.504
Leukemia, Myeloid
  1. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol. 2007 Mar; 20(1):29-37.
    View in: PubMed
    Score: 0.269
  2. Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007; 453-9.
    View in: PubMed
    Score: 0.266
  3. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact. 2005 May 30; 153-154:187-95.
    View in: PubMed
    Score: 0.236
  4. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.
    View in: PubMed
    Score: 0.204
  5. Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia? Leukemia. 2003 Mar; 17(3):488-91.
    View in: PubMed
    Score: 0.204
  6. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002 Sep; 16(9):1627-36.
    View in: PubMed
    Score: 0.197
  7. Myeloid leukemia after cytotoxic therapy and other hematotoxins. J Toxicol Environ Health A. 2000 Nov; 61(5-6):381-6.
    View in: PubMed
    Score: 0.173
  8. Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999 Jul 15; 94(2):803-7.
    View in: PubMed
    Score: 0.158
  9. Long-term follow-up of Cancer and Leukemia Group B studies in acute myeloid leukemia. Cancer. 1997 Dec 01; 80(11 Suppl):2210-4.
    View in: PubMed
    Score: 0.142
  10. Myeloid leukemia after hematotoxins. Environ Health Perspect. 1996 Dec; 104 Suppl 6:1303-7.
    View in: PubMed
    Score: 0.132
  11. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood. 1996 Oct 01; 88(7):2665-70.
    View in: PubMed
    Score: 0.131
  12. miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 2016 04 26; 7:11452.
    View in: PubMed
    Score: 0.127
  13. Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome. Leukemia. 1996 Apr; 10 Suppl 1:S23-5.
    View in: PubMed
    Score: 0.126
  14. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am. 1996 Apr; 10(2):293-320.
    View in: PubMed
    Score: 0.126
  15. Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia. Leukemia. 1995 Mar; 9(3):433-9.
    View in: PubMed
    Score: 0.117
  16. Acute myelomonocytic leukemia with abnormal eosinophils presenting as an ovarian mass: a report of two cases and a review of the literature. Gynecol Oncol. 1995 Feb; 56(2):307-11.
    View in: PubMed
    Score: 0.116
  17. Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol. 2014 Nov; 74(5):927-38.
    View in: PubMed
    Score: 0.113
  18. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study. Br J Haematol. 1992 Oct; 82(2):337-46.
    View in: PubMed
    Score: 0.099
  19. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
    View in: PubMed
    Score: 0.095
  20. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 2012 Mar 08; 119(10):2314-24.
    View in: PubMed
    Score: 0.094
  21. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011 Dec 22; 118(26):6920-9.
    View in: PubMed
    Score: 0.093
  22. Circulating immune complexes correlate with remission duration in acute myeloid leukemia. Leukemia. 1991 Feb; 5(2):131-7.
    View in: PubMed
    Score: 0.088
  23. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Aug 05; 116(5):788-92.
    View in: PubMed
    Score: 0.084
  24. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood. 2009 May 28; 113(22):5575-82.
    View in: PubMed
    Score: 0.077
  25. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood. 2008 Aug 01; 112(3):741-9.
    View in: PubMed
    Score: 0.073
  26. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood. 2007 Jun 15; 109(12):5164-7.
    View in: PubMed
    Score: 0.067
  27. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006 Aug 20; 24(24):3904-11.
    View in: PubMed
    Score: 0.065
  28. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood. 2006 Sep 01; 108(5):1677-83.
    View in: PubMed
    Score: 0.063
  29. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia. 2006 Jul; 20(7):1295-7.
    View in: PubMed
    Score: 0.063
  30. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006 Jul 01; 108(1):63-73.
    View in: PubMed
    Score: 0.063
  31. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Dec 20; 23(36):9234-42.
    View in: PubMed
    Score: 0.061
  32. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Aug 20; 23(24):5705-17.
    View in: PubMed
    Score: 0.060
  33. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
    View in: PubMed
    Score: 0.060
  34. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005 May 01; 105(9):3420-7.
    View in: PubMed
    Score: 0.057
  35. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan 20; 23(3):482-93.
    View in: PubMed
    Score: 0.057
  36. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004 Nov 01; 22(21):4290-301.
    View in: PubMed
    Score: 0.057
  37. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer. 2004 Sep 15; 101(6):1420-7.
    View in: PubMed
    Score: 0.057
  38. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol. 2004 Jun 15; 22(12):2410-8.
    View in: PubMed
    Score: 0.056
  39. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004 Mar 15; 22(6):1087-94.
    View in: PubMed
    Score: 0.055
  40. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer. 2004 Mar; 39(3):217-23.
    View in: PubMed
    Score: 0.055
  41. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004 Jun 01; 103(11):4036-42.
    View in: PubMed
    Score: 0.054
  42. P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults. Ann Hematol. 2004; 83 Suppl 1:S103-4.
    View in: PubMed
    Score: 0.054
  43. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood. 2003 Sep 01; 102(5):1613-8.
    View in: PubMed
    Score: 0.052
  44. Polymorphisms in the MLL breakpoint cluster region (BCR). Hum Genet. 2003 Jul; 113(1):80-91.
    View in: PubMed
    Score: 0.051
  45. Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23):14925-30.
    View in: PubMed
    Score: 0.050
  46. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol. 2002 Sep 15; 20(18):3878-84.
    View in: PubMed
    Score: 0.049
  47. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res. 2002 Sep; 8(9):2812-9.
    View in: PubMed
    Score: 0.049
  48. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15; 100(13):4325-36.
    View in: PubMed
    Score: 0.049
  49. Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proc Natl Acad Sci U S A. 2002 Mar 05; 99(5):3070-5.
    View in: PubMed
    Score: 0.047
  50. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001 Oct 01; 61(19):7233-9.
    View in: PubMed
    Score: 0.046
  51. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001 Jul 01; 19(13):3244-54.
    View in: PubMed
    Score: 0.045
  52. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics. 2001 Jan 15; 71(2):235-45.
    View in: PubMed
    Score: 0.044
  53. Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. Genomics. 2000 Jul 01; 67(1):28-39.
    View in: PubMed
    Score: 0.042
  54. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000 Apr 15; 95(8):2530-5.
    View in: PubMed
    Score: 0.042
  55. CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood. 1998 Oct 15; 92(8):2879-85.
    View in: PubMed
    Score: 0.038
  56. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53. Genes Chromosomes Cancer. 1997 Nov; 20(3):282-91.
    View in: PubMed
    Score: 0.035
  57. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A. 1997 Jun 24; 94(13):6948-53.
    View in: PubMed
    Score: 0.034
  58. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood. 1996 Sep 15; 88(6):1930-5.
    View in: PubMed
    Score: 0.033
  59. Familial myeloid leukemia associated with loss of the long arm of chromosome 5. Leukemia. 1996 Apr; 10(4):669-74.
    View in: PubMed
    Score: 0.032
  60. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood. 1993 Dec 15; 82(12):3705-11.
    View in: PubMed
    Score: 0.027
  61. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A. 1993 Jun 15; 90(12):5484-8.
    View in: PubMed
    Score: 0.026
  62. Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study. Exp Hematol. 1992 Nov; 20(10):1194-200.
    View in: PubMed
    Score: 0.025
  63. Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells. Blood. 1991 Mar 01; 77(5):1064-70.
    View in: PubMed
    Score: 0.022
  64. t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 1990 Dec 15; 76(12):2594-8.
    View in: PubMed
    Score: 0.022
  65. Methyl transferase activity in secondary leukemia. Basic Life Sci. 1990; 53:277-89.
    View in: PubMed
    Score: 0.020
  66. Association of a chromosomal 3;21 translocation with the blast phase of chronic myelogenous leukemia. Blood. 1987 Nov; 70(5):1338-42.
    View in: PubMed
    Score: 0.018
  67. Acral lividosis--a sign of myeloproliferative diseases. Hyperleukocytosis syndrome in chronic myelogenous leukemia. Arch Dermatol. 1987 Jul; 123(7):921-4.
    View in: PubMed
    Score: 0.017
  68. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007 Feb; 127(2):197-205.
    View in: PubMed
    Score: 0.017
  69. Rates of cholesterol biosynthesis are related to early differentiation in acute non-lymphocytic leukaemia cells. Br J Haematol. 1983 Jul; 54(3):459-66.
    View in: PubMed
    Score: 0.013
  70. Chromosome changes in hematologic malignancies. CA Cancer J Clin. 1981 Jul-Aug; 31(4):222-38.
    View in: PubMed
    Score: 0.011
  71. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. Cancer. 1985 Aug 01; 56(3):443-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.